Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 8-13

  Brown, Nancy J ^a   Ray, Wayne A ^a   Snowden, Mary ^a   Griffin, Marie R ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029783337     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90161-7     Document Type: Article

References (17)

1. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WHW, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988;260:967-70.
2. Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Speirs CF. Postmarketing surveillance of enalapril; I: results of prescription-event monitoring. Br Med J 1988;297:826-9.
3. Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med 1986;81:46-50.
4. Wood SM, Mann RD, Rawlins MD. Short Report. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J 1987;294: 91-2.
5. Cameron HA, Higgins TJC. Clinical experience with lisinopril: observations on safety and tolerability. J Hum Hypertens 1989;3:177-86.
6. Brown NJ, Nadeau JH. Does race predispose to angiotensin converting enzyme-associated angioneurotic edema [letter]. Ann Intern Med 1993;119:1224.
7. Burkhart GA, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Freiman JP, et al. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Safety [in press].
8. The International Classification of Diseases: 9th revision, clinical modification; vol 2. Hyattsville, MD: US Department of Health and Human Services; 1985.
9. McCullogh P, Neider JA. Generalized linear models. 2nd ed. New York: Chapman and Hall, 1989:193-208.
10. Materson BJ, Reda DJ, Cushman WC, Massie BM, Preis ED, Kahar MS, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328: 914-21.
11. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
12. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ, Curd JG, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983;308: 1050-4.
13. Levy SB, Lilley JJ, Frigon RP, Stone RA. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. J Clin Invest 1977;60:129-38.
14. Gainer J, Nadeau J, Ryder D, Brown N. Increased sensitivity to bradykinin in African Americans and hypertensives. J Allergy Clin Immunol [in press].
15. Brown NJ, Ryder D, Gainer J, Morrow JD, Nadeau J. The bradykinin-mediated effect of ACE inhibitors on is independent of their effect on prostaglandin [submitted].
16. Hedner T, Samuelsson O, Lindholm L, Andrén L, Wiholm BE. Precipitation of angioedema by anti-hypertensive drugs. J Hypertens 1991;9(suppl 6): S360-1.
17. Gianos ME, Klaustermeyer WB, Kurohara M, Tarnasky P, Gordon E. Enalapril induced angioedema. Am J Emerg Med 1990;8:124-6.